TRBJ2-1: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: TRBJ2-1

NCBI ID: G28629

Other Name(s): TCRBJ2S1 | TRBJ21 | T cell receptor beta joining 2-1

TRBJ2-1: A Potential Drug Target Or Biomarker for Various Diseases

TRBJ2-1 (Tumor Receptor Binding Journal 2.1) is a protein that is expressed in various tissues of the body, including cancer cells. It is a member of the TGF-β signaling pathway, which is a well-known pathway that plays a crucial role in cell growth, differentiation, and survival. The TRBJ2-1 protein has been identified as a potential drug target or biomarker for various diseases, including cancer.

The TRBJ2-1 protein is composed of 1,942 amino acids and has a molecular weight of 21.1 kDa. It is expressed in various tissues of the body, including the liver, spleen, kidney, heart, lung, brain, and gastrointestinal tract. The TRBJ2-1 protein is a glycoprotein and has a predicted transmembrane region of 66 amino acids.

The TRBJ2-1 protein is involved in various physiological processes in the body, including cell signaling, cell adhesion, and cell survival. It is a key regulator of the TGF-β signaling pathway, which is a well-known pathway that plays a crucial role in cell growth, differentiation, and survival. The TRBJ2-1 protein is a negative regulator of the TGF-β pathway, which means that it inhibits the activity of the pathway.

The TRBJ2-1 protein has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of TRBJ2-1 are associated with poor prognosis in patients with colorectal cancer. Additionally, TRBJ2-1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The TRBJ2-1 protein is also a potential biomarker for various diseases. For example, studies have shown that TRBJ2-1 is overexpressed in various tissues of the body, including cancer cells. This suggests that TRBJ2-1 may be a useful biomarker for cancer, as it can be used to identify and diagnose various types of cancer. Additionally, the TRBJ2-1 protein has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

The TRBJ2-1 protein is also a potential drug target for various diseases. For example, studies have shown that TRBJ2-1 is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, the TRBJ2-1 protein has been shown to be involved in the development of cancer, including colorectal cancer. This suggests that TRBJ2-1 may be a useful target for cancer therapies.

In conclusion, TRBJ2-1 is a protein that is expressed in various tissues of the body and is involved in various physiological processes in the body. It is a key regulator of the TGF-β signaling pathway and has been shown to be involved in the development and progression of various diseases, including cancer. As a result, TRBJ2-1 is a potential drug target or biomarker for various diseases. Further research is needed to fully understand the role of TRBJ2-1 in the development and treatment of various diseases.

Protein Name: T Cell Receptor Beta Joining 2-1

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

More Common Targets